52 results about "Phosphoryl choline" patented technology

A braided stent (1) for transluminal implantation in body lumens is self-expanding and has a radial expanded configuration in which the angle α between filaments is acute. Some or all of filaments (6,7) are welded together in pairs at each end (4,5) of the stent to provide beads (8), thereby strengthening the stent and assisting its deployment from a delivery device. The stent is preferably completely coated using a biocompatible polymeric coating, said polymer preferably having pendant phosphoryl choline groups. A method of making the stent by braiding and welding is described as well as a delivery device for deploying the device.The present invention provides a biocompatible crosslinked coating and a crosslinkable coating polymer composition for forming such a coating. The biocompatible crosslinked coating may be formed by curing a polymer of 23 mole % (methacryloyloxy ethyl)-2-(trimethylammonium ethyl) phosphate inner salt, 47 mole % lauryl methacrylate, 5 mole % γtrimethoxysilyl propyl methacrylate and 25 mole % of hydroxy propyl methacrylate. The crosslinkable coating polymer may include 23 mole % (methacryloyloxy ethyl)-2-(trimethylammonium ethyl) phosphate inner salt, 47 mole % lauryl methacrylate, 5 mole % γtrimethoxysilyl propyl methacrylate and 25 mole % of hydroxy propyl methacrylate.<?insert-end id="INS-S-00001" ?>

A polymer comprising phospholipid moieties and a biocompatible polymer backbone, a composition comprising the polymer and optionally a bioactive agent, an implantable devices such as a DES comprising thereon a coating comprising the polymer and optionally a bioactive agent, and a method of using the device for the treatment of a disorder in a human being are provided.

The present invention relates to implantable medical devices coated with phosphoryl choline acrylate polymer topcoat layer, an acrylate copolymer layer containing a therapeutic agent, and their use in the treatment of vascular diseases.

Permselective asymmetric membranes suitable e.g. for hemodialysis, hemodiafiltration and hemofiltration of blood, and having improved sieving characteristics providing enhanced removal of middle molecular weight substances, e.g. inflammatory mediators having a molecular weight between 20 and 40 kDa. The membranes comprise polyethersulfone and polyvinylpyrrolidone and are coated with hyaluronic acid or copolymers of 2-methacryloyloxyethyl phosphoryl choline and other vinyl polymerizable monomers. Processes for the preparation of these membranes, devices comprising these membranes, and the use of these membranes in hemodialysis, hemodiafiltration and hemofiltration of blood, as well as in bioprocessing, plasma fractionation and the preparation of protein solutions.

The invention discloses a preparation method of L-alpha-choline glycerophosphate. According to the method, (2S)-3-halogenated-1,2-propylene oxide and phosphoryl choline salt are used as the raw materials, and are subjected to esterification and hydrolysis reaction in a solvent to obtain the L-alpha-choline glycerophosphate crude product, and the crude product is subjected to silica gelcolumn chromatography and purification through ion exchange resin to obtain the L-alpha-choline glycerophosphate pure product. Compared with the prior art, the preparation method disclosed by the invention has the advantages that the operation is simpler; the adopted chiral material (2S)-3-halogenated-1,2-propylene oxide is cheap and easy to obtain; the prepared crude product is subjected to silica gelcolumn chromatography and purification through ion exchange resin to obtain the L-alpha-choline glycerophosphate product with higher quality, and the L-alpha-choline glycerophosphate content is more than 99%; the technical process is more suitable for large scale production.

The invention discloses a hydrophobic modified choline phosphorylated chitosan self-assembled nano microparticle and a preparation method thereof, belonging to the technical field of nano pharmaceutical preparations. The preparation method of the hydrophobic modified choline phosphorylated chitosan self-assembled nano microparticle comprises the steps of (1) making 6-O-triphenyl methylated chitosan obtained from chitosan modification react with disubstituted choline phosphonate to obtain a choline phosphorylated chitosan derivative; (2) introducing a hydrophobic group to the choline phosphorylated chitosan derivative through an N-acylation reaction to obtain a hydrophobic modified choline phosphorylated chitosan derivative; and (3) dispersing the hydrophobic modified choline phosphorylated chitosan derivative in a water solution, stirring and implementing ultrasonic treatment to obtain the hydrophobic modified choline phosphorylated chitosan self-assembled nano microparticle. The prepared hydrophobic modified choline phosphorylated chitosan self-assembled nano microparticle can inhibit non-specificity protein adsorption, and is easy to enter into cells, thus benefiting for drug delivery.

The embodiment of the invention discloses a synthesis method of L-alpha-glyceryl phosphoryl choline. The synthesis method comprises the following steps of: adding lecithin into a methanol solution, adding an alkali metal alkoxide catalyst into the solution, and performing hydrolysis reaction to remove an acyl group; regulating the pH of the solution to 5-6 by using an organic acid or an inorganic acid; extracting the solution after regulating the pH by using petroleum ether, and removing fat-soluble impurities in the solution; further removing inorganic salts and the impurities through strongly acidic, strongly alkaline, weakly acidic and weakly alkaline resin to obtain a sticky matter-like L-alpha-glyceryl phosphoryl choline crude product; and dissolving the sticky matter-like L-alpha-glyceryl phosphoryl choline crude product with methanol, adding acetone to precipitate crystals, and then performing suction filtration and drying to obtain a white solid finished product. The synthesis method disclosed by the invention has the advantages of simple process, low price of raw materials, easiness in acquisition of the raw material, simplicity in purification, low equipment requirements and easiness in implementation of industrial transformation.

A phosphatidic biological degradable polyester and its production are disclosed. The production is carried out by phosphatidic group of phosphoryl choline with bionic function condensing reacting, covalent interlinking onto biological degradable polymer chain, and obtaining degradable polymer with phosphatide modification. It achieves good biological degradability, biological compatibility, and self-combing ability for medicine releasing carrier materials.

A copolymer comprising (a) one or more pendant group segments and (b) one or more polyol segments, each of said segments being linked to one or more further segments which may be the same or different,

wherein said one or more pendant group segments are the same or different and are selected from:

• (i) siloxane segments;
• (ii) segments containing phosphoryl choline or a derivative or analogue thereof;
• (iii) segments containing a di- or trifluoromethyl group;
• (iv) heparin-like segments containing a group of formula (XII)

D-N═N—Ar—SO₃⁻  (XII)

wherein D is an aliphatic or aromatic group and Ar—SO₃⁻ comprises one or more linked aryl and/or heteroaryl groups, at least one of the aryl and/or heteroaryl groups having an SO₃⁻ substituent; and

• (v) segments containing a group of formula (I)

[P]_n′-[Lys]_n-Lys-[Spacer]-Lys-[Al]_x   (I)

wherein:

• • [Al] is an inert amino acid;
  • x is 0, 1, 2 or 3;
  • [Spacer] is a fatty acid, amino acid, peptide or PEG;
  • [P]_n′-[Lys]_n is a dendritic structure formed from n lysine groups and terminating in n′ groups P;
  • n is an integer of from 1 to 15;
  • n′ is zero or an integer of up to 16; and
  • each P is the same or different and is an amino acid or a peptide having up to 25 amino acids,

and wherein at least a part of each of said pendant group segment(s) is on a side chain of the copolymer.

The copolymer is useful in the production of implantable devices such as vascular grafts.

The invention discloses a group of plasma metabolism micromolecular markers related to lung cancer early diagnosis and an application thereof. The plasma metabolism micromolecular markers comprise oneor more of the following markers: propionic acid, aspartic acid, furan glucoside, citric acid, allose, talose, galactopyranose, pyruvic acid, tryptophan, leucyl proline, glyceryl phosphoryl choline,oleoyl carnitine, lysophosphatidyl choline (18:3), lysophosphatidyl choline (18:2), lysophosphatidyl choline (18:1), lysophosphatidyl choline (22:6), lysophosphatidyl ethanolamine (20:0), lysophosphatidyl ethanolamine (18:2), and complex aminoacyl valine. Compared with the traditional protein biomarkers, the group of the provided markers has the stronger outcome relevance with diseases, and is stable, minimally invasive, and easy to detect, capable of greatly improving the sensitivity and the specificity of the related disease diagnosis, and suitable for the early clinical diagnosis and monitoring of lung cancer.

The invention relates to a detection method of a glycerin phosphoryl choline injecta related material. In the method, high-performance liquid chromatography (HPLC) is adopted for measurement, a chromatographic column SCX (Strong Cation Exchange) is utilized as chromatographic column, and water the pH value of which is regulated to 1.5 by trifluoroacetic acid is utilized as a mobile phase, and theflow velocity is 1.0 ml/min, and an evaporative light-scattering detector is utilized for detection; and by utilizing the method, the detected glycerin phosphoryl choline injecta related material accounts for no more than 4.0%, and a definite value can be calculated. The detection method provided by the invention can be used for accurately detecting the content of the glycerin phosphoryl choline injecta related material, thus better guaranteeing the safety and effective of medications.

The invention discloses a method for determining the content of GPC (glycerophosphoryl choline) in three types of novel medicines GPC by utilizing a solid nuclear magnetic resonance internal standard method. The method mainly comprises the following steps: adding internal standard hexamethylbenzene in a test sample, acquiring a 13C NMR spectrogram of a sample by adopting a Bruker Avance III 400MHz, a nuclear magnetic resonance spectrometer and a wideband solid CP/MAS probe, and calculating the content of GPC by the 13C peak area of the methyl group contained in the GPC and hexamethylbenzene. According to the method disclosed by the invention, the structure authentication and quantitative analysis of the GPC are completed synchronously, so that the technical problems of the content determination of three types of novel medicine GPC standard substances are solved; the method has very great significance to the GPC development of three types of novel medicines GPC and interest protection of consumers and the healthy development of the GPC medicine industry of our country, and provides reference for the subsequent research of the nuclear magnetism quantitative analysis of other medicaments.

The invention discloses a phosphoryl choline polymer containing aldehyde group, and the polymer is a binary copolymer composite synthesized of Vinyl monomers containing aldehyde group and Vinyl monomers containing phosphorus acyl choline through radical polymerization. Furthermore, the invention discloses the preparation method and the application of the polymer. The polymer is used for coating the surface of to-be-decorated material after being mixed with polyamino material, the reaction of the aldehyde group and the amidogen in the coating layer are controlled by temperature, so as to enable the density of the coating layer to be increased, and achieve the purpose of fixing phosphoryl bile bases on the surface of the material and obtain a coating layer with a structure imitating of cell outer membrane. The protein absorption and blood platelet adhesion of the coating layer are remarkably decreased, the biocompatibility is remarkably improved, and the phosphoryl choline polymer has great academic values and broad application prospects in the filed of tissue engineering, drug controlled release, gene therapy, biosensor and the like.

The invention provides a method for artificially synthesizing phospholipid DPPC (dipalmitoyl phosphatidylcholine).The target product, DPPC, is synthesized from glyceryl phosphoryl choline and palmitic acid through condensation reaction.The method is simple in step, mild in reaction and suitable for industrial production.The prepared DPPC can be used for various medicines such as injection, tablets and capsules as a pharmaceutical adjuvant.

The invention discloses a low-temperature plasma induced membrane-type artificial lung graft modification method. The modification method includes the following steps that poly 4-methyl-1-amylene membrane materials for a membrane-type artificial lung are placed into a cavity of a plasma processing instrument, working gas is any one or two of pure ammonia gas, pure oxygen, pure argon and pure carbon dioxide, the pressure of the working gas is kept to be 20 Pa, the materials are processed for 1-5 min at the discharge power of 30-300 W, the gas flow is 30 ml/min-120 ml/min, phosphoryl choline compound steam is led into the cavity to induce vapor phase grafting, the steam pressure is stabilized to be 20 Pa, and the materials are processed for 1-5 min at the discharge power of 30-300 W. According to the method, the artificial lung membrane materials are modified through the low-temperature plasma technology, the process is simple, consumed time is short, the efficiency is high, the energy consumption is low, the biocompatibility of a poly 4-methyl-1-amylene (PMP) membrane is obviously improved, and the transmission performance of O2 and CO2 is slightly reduced compared with that before modification, however, the method still has wide medical application prospects.

The invention relates to a simulated erythrocyte membrane with high degree of blood compatibility. Medical polyvinyl chloride and phosphoryl choline high molecular polymer are used as raw materials; and the phosphoryl choline high molecular polymer is fixed on the surface of the medical polyvinyl chloride substrate to form the simulated erythrocyte membrane with high degree of blood compatibility. After the obtained simulated erythrocyte membrane contacts with human blood for 30 minutes, the surface of the membrane keeps smooth and clean and has no hemagglutination phenomenon, so the simulated erythrocyte membrane shows favorable surface anticoagulation.

The invention discloses a novel bis-amidogen phosphoryl choline compound Lys-EG-PC and a preparation method thereof and aims to provide the phosphoryl choline compound capable of being used for a surface treating agent or a surface treating agent raw material. The compound of the type can furthermore directly serve as a dressing agent, a chain extender or a cross-linking agent for decorating surfaces of various base materials or modifying the base materials so as to improve blood compatibility of high molecular materials, lower protein adsorption and reduce cell sediment, and the compound has huge academic value and broad prospect in the fields of tissue engineering, drug controlled release, gene therapy, cosmetics and the like. Steps are simple, operation is convenient to perform, and practicability is high.

The invention relates to a soft capsule for improving the cranial nerve function and a preparation method thereof. The soft capsule comprises content and a capsule shell material; the content comprises glyceryl phosphoryl choline and a solvent, wherein the glyceryl phosphoryl choline accounts for 60-95% of the total weight of the content; the solvent accounts for 5-40% of the total weight of the content; the solvent comprises one or several of water, glycerol, sorbitol, sorbitan, glycerol triacetate, polyethylene glycol 200, polyethylene glycol 400 and propylene glycol; and the capsule shell material comprises one or several of gelatin, water, glycerol, sorbitol, sorbitan, methylparaben, ethylparaben, propylparaben, titanium dioxide and iron oxide yellow. The preparation method comprises the following steps of: pressing a solution A prepared by the glyceryl phosphoryl choline and the solvent and a solution B prepared by the capsule shell material into soft capsules by a soft capsule machine; and drying to obtain the soft capsule for improving the cranial nerve function.

The invention belongs to the field of biological medicine and relates to S. cerevisiae strain for producing citicoline through bioconversion and application of the S. cerevisiae strain, namely the S. cerevisiae strain of high activity CMP (cytidine monophosphate) kinase and high activity phosphoryl choline-cytidyltransferase and the application of the S. cerevisiae strain in the production of citicoline through bioconversion. The S. cerevisiae strain provided by the invention has a classification name of S. cerevisiae, and has the Preservation No. of CGMCC7978 in CGMCC (China General Microbiological Culture Collection Center).